Abstract: A method, device, or system for treating eye disorders or conditions, comprising restoring or increasing blood flow or blood flow rate in an artery that supplies blood to or in the eye, thereby increasing the amount of nutrient(s) that reaches the eye or a portion thereof. The invention also includes methods, devices, or systems for treating eye disorders or conditions which use reverse flow or retrograde flow structures and systems during the treatment of the eye disease.

Abstract: A method, device, or system for treating eye disorders or conditions, comprising restoring or increasing blood flow or blood flow rate in an artery that supplies blood to or in the eye, thereby increasing the amount of oxygen that reaches the eye or a portion thereof.

Abstract: A probe coupling apparatus can be provided which can include, e.g., at least two opposing edges, one of the edges being configured to receive a tip of a probe. The exemplary apparatus can also include an orifice provided between the edges and a portion provided between the opposing edges and extending along the orifice. The portion can have a structure such that, when a force is applied to a section of the portion, a cross-sectional area of the orifice is increase, and, when the force is released, the area is decreased.

Abstract: A method, device, or system for treating eye disorders or conditions, comprising restoring or increasing blood flow or blood flow rate in an artery that supplies blood to or in the eye, thereby increasing the amount of nutrient(s) that reaches the eye or a portion thereof. The invention also includes methods, devices, or systems for treating eye disorders or conditions which use reverse flow or retrograde flow structures and systems during the treatment of the eye disease.

Abstract: There is provided herein a disclosure and specification of invention(s) relating to devices and methods for percutaneous access and treatment of vascular structures in the rear of the eye, including treatment for the symptoms related to Wet Age Related Macular Degeneration by removal of stenosis of the OA, thereby restoring normal, or near normal, blood flow to the rear of the eye, including the retina and associated structures. Also provided herein is a disclosure and specification of invention(s) relating to methods and devices for selective manipulation of Intraocular Pressure (IOP) be means of mechanical force for the purpose of inducing retrograde flow in the ophthalmic vasculature.

Abstract: There is provided herein a disclosure and specification of invention(s) relating to devices and methods for percutaneous access and treatment of vascular structures in the rear of the eye, including treatment for the symptoms related to Wet Age Related Macular Degeneration by removal of stenosis of the OA, thereby restoring normal, or near normal, blood flow to the rear of the eye, including the retina and associated structures. Also provided herein is a disclosure and specification of invention(s) relating to methods and devices for selective manipulation of Intraocular Pressure (IOP) be means of mechanical force for the purpose of inducing retrograde flow in the ophthalmic vasculature.

Abstract: The present invention comprises an implant for placing inside the eye such that the implant comes into contact with the interior tissue of the eye such that it conforms to the inner globe geometry of the eye. Implants of the present invention may also be used to alter the focal length of the eye thereby providing a treatment method for the correction of myopia and hyperopia. The device may consist of several possible configurations, an open mesh structure, a solid metal ring, a solid polymer shape, a mesh polymer shape or combination of these. The shape may be a curve, a sphere, a ring or a combination thereof that are specifically shaped to approximate a desired portion of the interior globe of the eye in order to treat myopia or hyperopia.

Abstract: Coating compositions and methods for their preparation are described. The coating compositions can include a first copolymer produced by emulsion polymerization and derived from one or more monomers including one or more (meth)acrylates, one or more acid monomers, and optionally styrene. The first copolymer can have a Tg from ?50° C. to ?23° C. and is present in an amount of 10-50% by weight based on the total polymer content. The coating compositions can also include a second copolymer produced by emulsion polymerization and derived from one or more monomers including one or more (meth)acrylates, one or more acid monomers, and optionally styrene. The second copolymer can have a Tg from ?15° C. to 25° C. and is present in an amount of 50-90% by weight based on the total polymer content. Further described herein are dried coatings, methods for coating a substrate, and methods for producing a coating.

Abstract: A device for characterizing a luminal dimension, such as the aortic annulus, has also been developed. These include a balloon or basket with sensing and transmitting elements for assessing two or three dimensional shape of lumens using a guide wire and catheter. Sheath introducer devices were developed for percutaneous delivery of bioprosthetic valves during various percutaneous procedures, such as TAVI. A marker needle dispenser for pre-marking anatomical features that are either desirable to target or desirable to avoid has been developed. The needle contains a central passage or lumen for loading marker and spacer material. These are characterized by specific spacing, color, shape or diagnostic imaging criteria to facilitate passage through and placement within the vasculature. Hemostatic stents or balloons are used to prevent bleeding and facilitate closure at sites for entry of catheters or introducer sheaths into luminal structures, especially for procedures such as TAVI through the subclavian artery.

Abstract: The present invention comprises an implant for placing inside the eye such that the implant comes into contact with the interior tissue of the eye such that it conforms to the inner globe geometry of the eye. Implants of the present invention may also be used to alter the focal length of the eye thereby providing a treatment method for the correction of myopia and hyperopia. The device may consist of several possible configurations, an open mesh structure, a solid metal ring, a solid polymer shape, a mesh polymer shape or combination of these. The shape may be a curve, a sphere, a ring or a combination thereof that are specifically shaped to approximate a desired portion of the interior globe of the eye in order to treat myopia or hyperopia.

Abstract: Compositions and methods for their application are described herein. The compositions include a plurality of particles having a density of 1000 kg/m3 or less (e.g., a pre-expanded polymer) and a binder. Also described herein is a method of applying the composition onto a surface. The method includes blowing a plurality of particles having a density of 1000 kg/m3 or less in at least one first stream and spraying a binder in at least one second stream onto a surface. Further provided is an apparatus for spraying the composition.

Abstract: A process for preparing alkyl glyceryl sulfonate includes fractionally distilling an alkyl glyceryl epoxide mixture to afford alkyl glyceryl epoxide of formula IV: where R is a C4-12 alkyl, in at least about 98.0% purity by weight with respect to epoxidized compounds, the epoxidized compounds comprising the alkyl glyceryl epoxide of formula IV, dimer alkyl glyceryl epoxide of formula V, and trimer alkyl glyceryl epoxide of formula VI: where R is a C4-12 alkyl; and reacting the at least about 98.0% alkyl glyceryl epoxide of formula IV with a mixture of an alkali bisulfite and an alkali sulfite in a sulfonation reaction at a temperature, to afford the alkyl glyceryl sulfonate of formula I: where R is a C4-12 alkyl and M is an alkali metal.

Abstract: A process for preparing alkyl glyceryl sulfonate includes fractionally distilling an alkyl glyceryl epoxide mixture to afford alkyl glyceryl epoxide of formula IV: where R is a C4-12 alkyl, in at least about 98.0% purity by weight with respect to epoxidized compounds, the epoxidized compounds comprising the alkyl glyceryl epoxide of formula IV, dimer alkyl glyceryl epoxide of formula V, and trimer alkyl glyceryl epoxide of formula VI: where R is a C4-12 alkyl; and reacting the at least about 98.0% alkyl glyceryl epoxide of formula IV with a mixture of an alkali bisulfite and an alkali sulfite in a sulfonation reaction at a temperature, to afford the alkyl glyceryl sulfonate of formula I: where R is a C4-12 alkyl and M is an alkali metal.

Abstract: A data buffer management system and method between two different types of systems, The data buffer management system employs circular buffer chaining, wherein multiple state machines service buffer updates from multiple sources, dual buffer structures are maintained, mapping is provided between two different control block structures, and full duplex operation is supported. The data buffer management system manages use of a data buffer memory. A transmit operation is performed by transferring and storing data from one of the two different systems to the data buffer memory The data in the data buffer memory is converted and read by another of the two different systems. A receive operation is performed by transferring and storing data from the other of the two different systems to the data buffer memory.